| Beneficial effects of the combination of nifedipine and losartan in hypertensive Dahl salt-sensitive rats. | |
| | |
MedLine Citation:
|
PMID: 17666919 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The antihypertensive and organ-protective effects of the combination of the angiotensin II type 1 receptor blocker losartan and the calcium channel blocker nifedipine were examined in Dahl salt-sensitive rats. METHODS: The rats fed with a high-salt diet developed hypertension accompanied by aorta and heart hypertrophy, and impaired renal function. The animals were treated with losartan (30 mg/kg/day), nifedipine (7.8 mg/kg/day) or with a combination of both drugs for 8 weeks. At the end of the study systolic blood pressure, kidney function, organ weight, and mRNA expression were investigated. RESULTS: Losartan reduced significantly the systolic blood pressure as well as the aorta and left ventricular hypertrophy. Nifedipine and its combination with losartan had similar effects on the systolic blood pressure, aorta and left ventricular hypertrophy but only the combination treatment reduced the expression of transforming growth factor-beta1 in aorta and brain natriuretic peptide in left ventricle significantly. Nifedipine and the combination therapy reduced proteinuria and improved urine creatinine excretion. The expression of collagen III and IV in the kidney was significantly reduced by the combination therapy. CONCLUSION: These results indicate that although losartan and nifedipine were effective in lowering blood pressure and showed moderate organ protection, additional benefits can be expected by combination therapy with both compounds. |
| | |
Authors:
|
Hanna Tinel |
Related Documents
:
|
2830189 - Individual responses to converting enzyme inhibitors and calcium antagonists. 17227609 - Preliminary evaluation of the use of a cdma-based emergency telemedicine system. 1698129 - Suppression of repolarization-related arrhythmias in vitro and in vivo by low-dose pota... 12395979 - Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continu... 2912599 - Effects of calcium channel antagonists on carotid sinus baroreflex control of arterial ... 10737129 - Is there any difference between intermediate-acting and long-acting calcium antagonists... 21978219 - Radial pressure pulse and heart rate variability in normotensive and hypertensive subje... 17198909 - The g-231a polymorphism in the endothelin-a receptor gene is associated with lower aort... 16215389 - Effect of increased cardiac output on hepatic and intestinal microcirculatory blood flo... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of cardiovascular pharmacology Volume: 50 ISSN: 0160-2446 ISO Abbreviation: J. Cardiovasc. Pharmacol. Publication Date: 2007 Jul |
Date Detail:
|
Created Date: 2007-08-01 Completed Date: 2007-12-03 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7902492 Medline TA: J Cardiovasc Pharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 75-82 Citation Subset: IM |
Affiliation:
|
Product Related Research, Pharmacology, Pharma R&D Discovery Research, Bayer HealthCare AG, Wuppertal, Germany. hanna.tinel@bayerhealthcare.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiotensin II Type 1 Receptor Blockers
/
pharmacology* Animals Aorta / metabolism Blood Pressure / drug effects Calcium Channel Blockers / pharmacology* Drug Therapy, Combination Gene Expression Hypertension / chemically induced, drug therapy* Hypertrophy, Left Ventricular / complications, drug therapy Kidney / metabolism Losartan / pharmacology* Male Natriuretic Peptide, Brain / metabolism Nifedipine / pharmacology* Organ Size RNA, Messenger / metabolism Rats Rats, Inbred Dahl Sodium Chloride, Dietary Transforming Growth Factor beta1 / metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin II Type 1 Receptor Blockers; 0/Calcium Channel Blockers; 0/RNA, Messenger; 0/Sodium Chloride, Dietary; 0/Transforming Growth Factor beta1; 114471-18-0/Natriuretic Peptide, Brain; 114798-26-4/Losartan; 21829-25-4/Nifedipine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Potency and in vitro tolerance of organic nitrates: partially denitrated metabolites contribute to t...
Next Document: Resveratrol inhibits rat aortic vascular smooth muscle cell proliferation via estrogen receptor depe...